Interleukin-6 -634 C/G and -174 G/C Polymorphisms in Korean Patients Undergoing Hemodialysis.
10.3904/kjim.2012.27.3.327
- Author:
Jung Hwa RYU
1
;
Seung Jung KIM
Author Information
1. Division of Nephrology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea. sjkimwon@ewha.ac.kr
- Publication Type:Original Article
- Keywords:
Hemodialysis;
Inflammation;
Interleukin-6 polymorphism;
Vascular access failure
- MeSH:
Adult;
Aged;
Arteriovenous Shunt, Surgical/*adverse effects;
Asian Continental Ancestry Group/*genetics;
Case-Control Studies;
Chi-Square Distribution;
Enzyme-Linked Immunosorbent Assay;
Female;
Gene Frequency;
Genotype;
Graft Occlusion, Vascular/blood/ethnology/*genetics/physiopathology;
Humans;
Interleukin-6/blood/*genetics;
Kidney Failure, Chronic/blood/ethnology/genetics/immunology/*therapy;
Logistic Models;
Male;
Middle Aged;
Odds Ratio;
Phenotype;
Polymerase Chain Reaction;
*Polymorphism, Genetic;
Promoter Regions, Genetic;
*Renal Dialysis;
Republic of Korea;
Time Factors;
Treatment Outcome;
Vascular Patency/*genetics
- From:The Korean Journal of Internal Medicine
2012;27(3):327-337
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Chronic inflammatory status is a possible risk factor for vascular access dysfunction in hemodialysis (HD) patients, but susceptibility differences appear among individuals. Interleukin (IL)-6 is a well-known inflammatory cytokine with various polymorphisms. We examined whether IL-6 polymorphisms are associated with vascular access dysfunction in HD patients. METHODS: A total of 80 HD patients (including 42 diabetic patients) were enrolled. Polymorphisms in the IL-6 gene promoter (-634 C/G and -174 G/C) were studied using restriction length polymorphism polymerase chain reaction analysis. Vascular access patency was compared between the patient groups with respect to IL-6 polymorphisms. An additional 89 healthy individuals were enrolled in the control group. Plasma IL-6 levels were de termined by enzyme-linked immunosorbent assay. RESULTS: The GG genotype and G allele at position -634 in the IL-6 promoter were more frequently observed in HD patients than in controls. Furthermore, the distribution of the -634 polymorphism differed according to vascular access patency in non-diabetic HD patients. However, the G allele was not a significant risk factor for early access failure. No significant association appeared between the IL-6 -634 C/G polymorphism and plasma IL-6 levels. The C allele of the IL-6 -174 G/C polymorphism was not detected in our study population. CONCLUSIONS: The IL-6 -634 G allele appears with greater frequently in patients with end-stage renal disease and may be associated with vascular access dysfunction in non-diabetic HD patients.
